Zobrazeno 1 - 10
of 84
pro vyhledávání: '"329"'
Autor:
A Rios, JM Rodriguez-Fernandez, Rocío Parody, M Morey, Ayats R, Rozman C, Emili Montserrat, T Vallespi, Prados D, F Gomis
Publikováno v:
Blood. 64(3)
In previous studies, the prognostic value of bone marrow (BM) histologic patterns in chronic lymphocytic leukemia (CLL) has been demonstrated. In order to investigate whether such a value is independent of other prognostic parameters, a multivariate
Autor:
Romain Guieze, Anne Calleja, Loic Ysebaert, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Fontanet Bijou, Anne Quinquenel, Annie Brion, Kamel Laribi
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1741, 2019, Blood
Ibrutinib has revolutionized the management of RR CLL in the past 5 years, improving overall survival (OS) over standard chemo-immunotherapies (CIT) in the registration trials HELIOS and RESONATE. Recently, based on these two studies, a score has bee
Autor:
Alok A. Khorana, Fahrettin Covut, Yihong Zhou, Shafia Rahman, Shab E Gul Rahim, Sudha Amarnath
Publikováno v:
Blood. 132:1242-1242
Background:Venous thromboembolism (VTE) is a highly prevalent complication of cancer and its treatment and is commonly treated with anticoagulation1. However, there are limited data regarding the use of therapeutic anticoagulation in patients with br
Autor:
Auro Viswabandya, Hans A. Messner, Dennis Dong Hwan Kim, Jieun Uhm, Marc Poch Martell, Elizabeth Shin, Jeffrey H. Lipton, Fotios V. Michelis
Publikováno v:
Blood. 126:3139-3139
Introduction: Chronic graft versus host disease (cGVHD) is one of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Several prognostic factors have been proposed to predict the outcomes of cGVHD including progres
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Scott C. Kogan, Geoffrey D. Wool
Publikováno v:
Blood, vol 122, iss 21
The UCSF hematology laboratory uses the Precision Biologic LA Check and LA Sure reagents for the Russell’s viper venom time (RVVT), as part of the laboratory diagnosis of a lupus anticoagulant (LA). Currently, manufacturer’s FDA-approved guidelin
Autor:
Yasushi Miyazaki, Yoshihiro Hatta, Toru Sakura, Noriyoshi Iriyama, Hiroshi Handa, Masatomo Takahashi, Hisashi Sakamaki, Tomohiko Taki, Norio Asou, Shunichiro Yamaguchi, Tomoya Maeda, Shinya Satou, Shuichi Miyawaki, Sumihisa Honda, Shigeki Ohtake, Tomoki Naoe, Masafumi Taniwaki
Publikováno v:
Blood. 122:2608-2608
Background Immunophenotyping is a standard diagnostic procedure in leukemia, but unlike cytogenetic classifications, which are reliable indicators for prognostic interpretation, immunophenotyping has, thus far, yielded inconsistent results. Recently,
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
Mario Uhr, Francesco Forconi, Emanuele Zucca, Georg Stussi, Andrea Rinaldi, Francesco Bertoni, Michael Mian, Franco Cavalli, Ivo Kwee, Roberto Marasca, Gianluca Gaidano, Afua Adjeiwaa Mensah, Davide Rossi, Marco Ladetto
Publikováno v:
Blood. 120:3906-3906
Abstract 3906 The clinical course of CLL patients ranges from an indolent and chronic disease to a rapidly progressing leukemia or lymphoma necessitating aggressive treatment. Very recent data have shown that genomic complexity evaluated by conventio
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the